Iodine-131 tositumomab (Bexxar®) in relapsed/refractory non-Hodgkin's lymphoma: Update from the 2001 American Society of Hematology Meeting

Clinical Lymphoma

Volumn 2, Issue 4, 2002, Pages 209-211

  Gibson, Angelia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IODINE 131; TOSITUMOMAB; TOSITUMOMAB I 131;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; HUMAN; IONIZING RADIATION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0036226605     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70233-0     Document Type: Conference Paper

References (6)

1. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
2. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
3. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
4. Interim safety and efficacy results of Bexxar™ in a large multicenter expanded access study
5. Results of a randomized study of Bexxar™ (tositumomab and iodine I131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL)
6. Acute and delayed hematologic toxicities associated with Bexxar™ therapy are modest: Overall experience in patients with low-grade and transformed low-grade NHL